Stay updated on Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial page.

Latest updates to the Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial page
- Check5 days agoChange DetectedTwo additions were recorded on 2026-04-01 and 2026-04-02, and two deletions were recorded on 2026-03-24 and 2026-03-25, updating the study record.SummaryDifference0.1%

- Check12 days agoChange DetectedAdministrative updates were made to the study record on 2026-03-24 and 2026-03-25, with deletions on 2026-03-17 and 2026-03-18.SummaryDifference0.1%

- Check20 days agoChange DetectedAdditions on 2026-03-18 and 2026-03-17 include Revision: v3.5.0. Deletions on 2026-03-11 and 2026-03-10 include Revision: v3.4.3.SummaryDifference0.2%

- Check27 days agoChange DetectedRevision notes indicate an update to v3.4.3 on 2026-03-10 and 2026-03-11, replacing the previous v3.4.2.SummaryDifference0.2%

- Check34 days agoChange DetectedStudy record dates and last-updated timestamps were updated on 2026-03-03, 2026-02-11, and 2025-12 to reflect recent maintenance.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page now shows Revision: v3.4.2 and the prior funding notice and Revision: v3.4.1 have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial page.